RBC Bioscience Corporation (TPEX:6848)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
22.20
-0.25 (-1.11%)
Aug 19, 2026, 11:32 AM CST

RBC Bioscience Cash Flow Statement

Millions TWD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
21.0623.5421.576.433.7828.73
Depreciation & Amortization
15.8615.4717.5418.7519.2819.45
Other Amortization
1.171.170.550.450.460.41
Loss (Gain) From Sale of Assets
---00.02-0.010.54
Asset Writedown & Restructuring Costs
-----0.93
Provision & Write-off of Bad Debts
0.090.080.420.11-0.1-0.37
Other Operating Activities
-2.870.513.43-7.151.3-28.74
Change in Accounts Receivable
-0.98-12.89.092.48-0.8127.54
Change in Inventory
2.25.27-8.342.7849.59
Change in Accounts Payable
-0.890.38.05-6.99-13.04-65.31
Change in Unearned Revenue
0.610.130.790.06-1.111.06
Change in Other Net Operating Assets
5.166.842.83-3.73-7.14-19.11
Operating Cash Flow
41.440.5255.9313.216.6-25.3
Operating Cash Flow Growth
7.68%-27.55%323.45%100.03%--

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
0.54-6.44-2.13-4.99-9.96-449.72
Sale of Property, Plant & Equipment
--0-0.010.01
Sale (Purchase) of Intangibles
-6.67-6.67-8.19-1.47-0.09-0.39
Other Investing Activities
-0.36-2.320.957.4722.6524.44
Investing Cash Flow
-6.49-15.43-9.37112.61-425.67

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
--35203.46-404.06
Total Debt Issued
15-35203.46-404.06
Short-Term Debt Repaid
--25-10-5-24.65-6.35
Long-Term Debt Repaid
--39.23-43.9-208.89-4.59-8.84
Total Debt Repaid
-63.44-64.23-53.9-213.89-29.24-15.19
Net Debt Issued (Repaid)
-48.44-64.23-18.9-10.43-29.24388.87
Issuance of Common Stock
-----50
Common Dividends Paid
-4.28-4.28-12.98-14.53-11.8-14.38
Other Financing Activities
----0.29-
Financing Cash Flow
-52.72-68.52-31.88-24.96-40.75424.49

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Cash Flow
-17.8-43.4214.68-10.75-21.54-26.48

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
41.9534.0853.88.21-3.36-475.02
Free Cash Flow Growth
36.17%-36.64%554.94%---
Free Cash Flow Margin
19.01%15.51%26.21%4.76%-1.93%-189.12%
Free Cash Flow Per Share
2.922.373.750.57-0.23-35.11
Levered Free Cash Flow
69.8716.838.362.9519.92-460.85
Unlevered Free Cash Flow
75.622.8644.819.224.66-456.89

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
9.759.7510.2710.087.415.94
Cash Income Tax Paid
5.695.6928.55036.35
Change in Working Capital
6.09-0.2512.43-5.4-18.11-46.24